Stocks · News reference
Morgan Stanley analyst Maxwell Skor has initiated coverage of REGENXBIO (RGNX) with a Buy rating and a price target of $18.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-10-16 AccNo: 0001193125-26-423376 Size: 147 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Regenxbio (NASDAQ:RGNX) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to
Mizuho analyst Graig Suvannavejh initiates coverage on Regenxbio (NASDAQ:RGNX) with a Outperform rating and announces Price Target of $22.